Neumora Therapeutics, Inc.

Blackthorn Therapeutics, Inc.

Chdi Foundation, Inc.

Jones, Robert M.

Brandt, Gary

Knight, Chris

Hardick, David

Urbano, Mariangela

Jason Tierney

Chris Knight

Mariangela Urbano

David Hardick

Gary Brandt

Chris Lock

Celia Dominguez

Alan Findlay Haughan

Mark Stuart Chambers

Christopher A Luckhurst

Andrew J Stott

Matthew Randolf Lee

Michel C Maillard

Michael Barnes

Tammy Ladduwahetty

Provided herein are certain inhibitors of ROCK (rho-kinases or rho-associated kinases), which are useful as medicament, for the treatment Huntington's disease in particular.

Rho kinase inhibitors and compositions and methods of use thereof

Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q, Q, Q, R, R, Rand X are as defined herein.

Vasopressin receptor antagonists and products and methods related thereto

Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R, R, R, Rand X are as defined herein.

Growing community of inventors

Saffron Walden, United Kingdom

Jason Tierney